Neurizon Therapeutics Limited has released a press release.
NIH funds Expanded Access Program for NUZ-001 in ALS
Earlier from Neurizon Therapeutics
- Neurizon Appoints Chief Executive Officer
- Appendix 4E and 2026 Annual Report
- Neurizon Enters Strategic R&D Financing Facility
- HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027